Wells Fargo Reiterates Buy Rating on Rhythm Pharmaceuticals

Wells Fargo's analyst Derek Archila reiterated a buy rating for Rhythm Pharmaceuticals, Inc. (NasdaqGM:RYTM) on June 15, 2026. The firm set a price target of $155 for the biopharmaceutical company, which focuses on treatments for rare neuroendocrine diseases.

Other Institutional Activity in Rhythm Pharmaceuticals

Several institutional investors have made moves in Rhythm Pharmaceuticals recently. RA Capital Management, L.P. held steady with 6,666,837 shares valued at approximately $579.8 million. BlackRock, Inc. trimmed its position by 60,183 shares, leaving it with 6,237,151 shares worth about $542.4 million. Baker Bros. Advisors LP maintained its holdings at 5,604,483 shares valued at $487.4 million. Primecap Management Co/CA/ reduced its stake by 61,160 shares to 3,417,509, valued around $297.2 million. Meanwhile, Vanguard Portfolio Management LLC and Vanguard Capital Management LLC both established new positions, holding 3,040,718 and 2,967,825 shares, respectively.

Rhythm Pharmaceuticals Stock Snapshot

Shares of Rhythm Pharmaceuticals are currently trading at $88.38 on the NasdaqGM. The company has a market capitalization of approximately $6.15 billion. Rhythm Pharmaceuticals is not profitable, reflected in a negative forward P/E ratio of -120.99. The stock has a beta of 1.923, indicating higher volatility compared to the broader market. Over the past 52 weeks, the stock has ranged from a low of $60.70 to a high of $122.20, with a 50-day moving average of $87.89 and a 200-day moving average of $97.91.

Recent Earnings

In its latest earnings report, Rhythm Pharmaceuticals posted revenue of $217.2 million, showing a growth rate of 83.8%. However, the company reported a net margin of -93.33% and a return on equity of -101.16%, indicating ongoing challenges in achieving profitability. The next earnings release is scheduled for August 4, 2026.

Insider Buying and Selling at Rhythm Pharmaceuticals, Inc.

Several insider transactions have occurred at Rhythm Pharmaceuticals. On May 18, 2026, CFO Hunter Smith bought 3,000 shares at an average price of $17.87. On the same day, he also sold 3,000 shares. Corporate Controller & CAO Christopher Paul German bought 4,442 shares on May 15, 2026, at an average price of $42.17 and sold 4,643 shares at $92.21.

Analysts Set New Price Targets

On June 15, 2026, Wells Fargo maintained its buy rating on Rhythm Pharmaceuticals with a price target of $155. Previously, Canaccord Genuity and RBC Capital also maintained buy ratings with targets of $143 and $137, respectively. The consensus among analysts is a strong buy, with a mean price target of $138.93 based on 15 analyst opinions.

About Rhythm Pharmaceuticals

Rhythm Pharmaceuticals, Inc. is a biotechnology company based in Boston, Massachusetts. It develops treatments for rare neuroendocrine diseases, with its leading product candidate, IMCIVREE, targeting conditions like POMC deficiency obesity and Bardet-Biedl syndrome. The company, led by CEO Dr. David P. Meeker, employs 414 people and is involved in various clinical trials for innovative therapies addressing complex medical conditions.

Bottom Line

Wells Fargo's reiterated buy rating with a $155 target reflects continued confidence in Rhythm Pharmaceuticals' potential, despite its current lack of profitability. Investors track these ratings to gauge analyst sentiment and market expectations. As a reminder, analyst opinions are forward-looking and reflect the firm's assessment of future performance.